Ion Opticks–Sher D: management, 202602– Chief Commercial Officer before Revvity + Oxford Immunotec + Siemens Healthineers

	Period	2026-02-01
	Organisation	Ion Opticks Pty Ltd. (IonOpticks)
	Organisation 2	Revvity Inc. (NYSE: RVTY)
	Group	Revvity (Group)
	Product	liquid chromatography (LC)
	Product 2	LC/MS (liquid chromatography/mass spectrometry)
	Person	Sher, Darren (Ion Opticks 202602– Chief Commercial Officer before Revvity + Oxford Immunotec + Siemens Healthineers)

Ion Opticks Pty Ltd.. (2/3/26). "Press Release: IonOpticks Appoints Darren Sher as Chief Commercial Officer to Lead Global Commercial Strategy".

The appointment strengthens IonOpticks’ commercial leadership as the company scales its global operations.

IonOpticks, a world-leading provider of liquid chromatography solutions, today announces the appointment of Darren Sher as Chief Commercial Officer; a strategic Executive role established to provide coordinated leadership across global sales, marketing, customer support, and aligned customer processes as the company continues to scale its business internationally.

With more than 25 years of experience across life science tools and clinical diagnostics, Darren brings exceptional depth in global commercial leadership and a proven track record of building high-performing teams and driving business growth across diverse international markets.

“We’re delighted to welcome Darren as Chief Commercial Officer,” said Xavier Perronnet, CEO at IonOpticks. “This is a pivotal appointment as we continue to scale the business and broaden our commercial activity globally. Darren brings a strong track record of driving growth across life science and diagnostics organisations. He will provide the leadership to execute our commercial strategy and to further align and optimise our customer related processes worldwide.”

Darren joins IonOpticks from Revvity, where he served as General Manager of the Infectious Disease Division, responsible for global strategy, product commercialisation, and channel expansion. Prior to Revvity, he was Chief Commercial Officer at Oxford Immunotec, leading global sales, technical service, marketing, and market access through a period of significant international growth.

Darren has also held senior leadership roles at Siemens Healthineers, most recently as Senior Vice President for point of care testing across Europe and Africa, where he built high-performing regional teams and strengthened commercial execution across diverse markets. Throughout his career, he has demonstrated exceptional ability to drive revenue growth, expand market presence, and align commercial operations with strategic business objectives.

Darren holds a BSc in Biomedical Engineering and an MSc in Marketing, a combination that underpins his ability to translate scientific innovation into scalable commercial platforms. This unique blend of technical understanding and commercial acumen has been instrumental throughout his career in bridging the gap between cutting-edge technology and market success.

“I’m thrilled to join IonOpticks at such an exciting time in the company’s growth trajectory,” said Darren. “IonOpticks has established itself as a leader in proteomics innovation, and I’m looking forward to working with the talented team to strengthen our global commercial capabilities and deliver exceptional value to our customers worldwide.”

In his new role, Darren will provide executive oversight and strategic direction across all commercial functions, ensuring cohesive execution of IonOpticks’ global go-to-market strategy while building the infrastructure and processes needed to support continued international expansion.
Executive Appointment

MEDIA CONTACT

Michael Sinden
communications@ionopticks.com

ABOUT IONOPTICKS

IonOpticks is a global leader in high-performance chromatography solutions, empowering the research community to push the boundaries of LC-MS and advanced proteomics.

By dramatically enhancing the sensitivity and reliability of mass spectrometry, IonOpticks enables scientists and clinicians to uncover more insights from every sample. These innovations drive discovery across diverse applications, including drug development, phosphoproteomics, shotgun proteomics, and clinical research. Trusted by leading laboratories worldwide, IonOpticks combines cutting-edge technology with a commitment to advancing biological and medical science.